· Summary
· Immediate Mx
· Dantrolene pharmacology
Definition |
· Rare, life-threatening hypermetabolic reaction to volatile anaesthetics or suxamethonium |
Aetiology |
· Autosomal dominant mutation RYR1 gene encoding the skeletal muscle ryanodine receptor (RR) and ion channel · 1 in 200,000 |
Pathophysiology |
· Continuous, excessive Ca2+ release · Continuous skeletal muscle contraction · ↑↑VO2, ↑↑VCO2 · ↑HR, ↑etCO2, ↑temp |
Complications |
· Rhabdomyolysis · Acidosis · Arrhythmia · Death (80% mortality if untreated) |
Basics |
· Call for help, need many hands · Abandon surgery · Stop the offending agent(s) ASAP o Cease volatile, FGF >10L/min to flush circuit, ↑FiO2 to 100% o No more suxamethonium · Start IV sedation e.g. propofol 30mL/h |
ABC |
· A: insert ETT · B: IPPV, note ↑↑MV required · C: ensure BP within safe limits, insert arterial line · D: sedate e.g.propofol 200mg/h |
Dantrolene ASAP |
· Bolus dose: 2.5mg/kg rapidly ± repeat; may require >10mg/kg · Infusion for up to 24h: 1mg/kg/h |
Cool to 37C |
· Remove clothing and blankets · Cold IV saline · Cold bladder or intraperitoneal irrigation |
Treat complications |
· e.g. hyperkalemia |
Take to ICU |
· Observation ~24 hours · +/- dantrolene infusion |
Physicochemical |
· Glass vial, orange powder · 20mg dantrolene, 3mg mannitol (solubiliser), NaOH · Add to 60mL H2O · Needs mixing +++ (poorly water soluble) · ± thrombophlebitis · ± necrosis if extravasated |
Pharmacokinetic |
· IV or oral · Low VD 0.6L/kg · 90% plasma protein bound · Hepatic metabolism Phase 1; active metabolite 5-OH-dantrolene · Renal excretion of metabolites · t1/2β 9 hours |
Pharmacodynamic |
· Competitive antagonist at the skeletal muscle RR -> ↓Ca2+ release -> post-junctional relaxation · Effects: skeletal muscle relaxation, resp paralysis · No effect on cardiac or CNS ryanodine receptor · Side effects rare: o ↑LFTs o APO from IV fluid +++ |
Feedback welcome at ketaminenightmares@gmail.com